Status:
ACTIVE_NOT_RECRUITING
Extended Access of Momelotinib in Adults With Myelofibrosis
Lead Sponsor:
GlaxoSmithKline
Conditions:
Neoplasms
Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-es...
Eligibility Criteria
Inclusion
- Key
- Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301
- Able to comprehend and willing to sign the informed consent form
- Key
Exclusion
- Known hypersensitivity to MMB, its metabolites, or formulation excipients
- NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Key Trial Info
Start Date :
May 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2026
Estimated Enrollment :
237 Patients enrolled
Trial Details
Trial ID
NCT03441113
Start Date
May 3 2018
End Date
December 31 2026
Last Update
May 16 2024
Active Locations (224)
Enter a location and click search to find clinical trials sorted by distance.
1
IC Irvine Health
Orange, California, United States, 92868
2
GSK Investigational Site
Stanford, California, United States, 94305-5821
3
Stanford Hospital and Clinics
Stanford, California, United States, 94305
4
GSK Investigational Site
Aurora, Colorado, United States, 80045